Abstract: Non steroidal anti-in®ammatory drugs are the most widely used medicines for relief of pain. These drugs have some side e¬ects, particularly toxicity in the gastrointestinal tract and kidneys. Various approaches have been used for obtaining safer anti-in®ammatory drugs. In this review we have summarized the recent developments in the following areas; (i) Mode of action of NSAIDs, (ii) Role of COX-1 & COX-2 in in®ammation, (iii) Di¬erent approaches used to improve gastric tolerance i.e chemical manipulation, formulation & co-administration, development of non speci c (COX
Introduction
Any kind of health problem human beings face involve's some degree of pain, and to solve this problem, it is necessary to know the mechanism behind the feeling of pain. For centuries some relief was provided by natural remedies such as white willow bark (Salix alba) and myrtle (Myrtus communis). Then a break through occurred when it was discovered that prostaglandins are the cause of in°ammation and the subsequent production of pain. By stopping the formation of prostaglandins one can stop the pain. Out of this knowledge came the development, manufacture and use of pain relieving phar-maceuticals known as non-steroidal anti-in°ammatory drugs. A number of non steroidal anti-in°ammatory drugs such as ibuprofen, fenoprofen, indomethacin, phenylbutazone, diclofenac, oxyphenylbutazone, benorylate, caprofen, benoxaprofen, tiopinac, ketoprofen, sulindac and aspirin are available in the market [1] . Nonsteroidal antiin°ammatory drugs are not only useful in treatment of in°ammation & pain but also reduces the risk of many cancers [2] , [3] and even Alzheimer's disease [4] .
Prostaglandins are thought to be released at the site of in°ammation when leukocytes are attracted to the in°ammed or injured areas. All mammalian cells except red blood cells can produce prostaglandins, and when injured, the cells release large amounts of these substances. NSAIDs are nonselective inhibitors of the enzymes which convert arachidonic acid to prostaglandins and are thus associated with adverse gastrointestinal e®ects, such as gastritis, dyspepsia, gastroduodenal ulcers and bleeding [5] . It is not certain whether all NSAID's currently used will cause the same risk for gastrointestinal ulcers. It is not easy to adjust for di®erences in doses when comparing NSAIDs. In one case, 1200mg of ibuprofen per day or less resulted in a lower incidence of complicated ulcers that required hospitilization than many of the other NSAIDs (for example ketoprofen, tolmetin and diclofenac); this di®erence however was not seen at higher doses of ibuprofen [6] . Certain NSAIDs that are mildly selective for COX-2 such as etodolac & nabumetone may lead to a some what lower risk for ulcers than traditional NSAIDs [7] , [8] . In this review we will summarize di®erent approaches used to improve the gastric tolerance of NSAIDs. Before describing di®erent approaches about the development of safer anti-in°ammatory drugs it will be worth while to review what is known as the mode of action of anti-in°ammatory drugs and role of COX-1 & COX-2 in in°ammation.
Mode of action of in°ammation inhibitors
The ability of NSAIDs to inhibit prostaglandin synthesis appears to be positively correlated with their anti-in°ammatory e®ect [1, 9] The relative contribution of this and other mechanisms of action is not known. Formation of other arachidonic acid metabolites including leukotrienes and 5-hydroxyeicosatetraenoic acid (5-HETE) have been reported to be inhibited by high concentration of diclofenac. Diclofenac may inhibit the migration of leukocytes, including polymorphonuclear leukocytes, into in°ammatory sites. However, inhibition of leukotriene formation and migration of leukotriene do not appear to result from direct diclofenac-induced inhibition of lipoxygenase. Lysosomal enzyme release from polymorphonuclear leukocytes, is inhibited by diclofenac and superoxide production and chemotaxis of polymorphonuclear leukocytes may be inhibited by diclofenac.
The exact mechanisms of the anti-in°ammatory e®ect of salicylates have not been fully elucidated due in part to the complexity of the in°ammatory response. The antiin°ammatory e®ect of salicylates may be due in part to inhibition of prostaglandin synthesis and release during in°ammation. Although aspirin and other salicylates inhibit cyclooxygenase and thereby decrease production of prostaglandins, they apparently do not inhibit the formation of leukotrienes. In the case of indomethacin, it has also been postulated that indomethacin as an inhibitor of phosphodiestrase, may increase intercellular conc. of cyclic adenosine monophosphate (AMP) which may play a role in the in°amma-tory response. In supratherapeutic concentrations, indomethacin depresses the synthesis of mucopolysaccharides through uncoupling of oxidative phosphorylation. Indomethacin and some other NSAIDs may also interfere with prostaglandin mediated formation of autoantibodies that are involved in the in°ammatory process, by inhibiting cyclooxygenase. Indomethacin does not possess glucocorticoid or adrenocorticoid stimulating properties.
Xie et al. [10] discovered the COX-2 enzyme in 1991 and found the existence of two di®erent isoforms of the enzyme cyclooxygenase i.e COX-1 and COX-2. The role of COX-1 is a constant physiological \house keeper" isoform and is produced throughout the body. It is involved in the regulation of day-to-day cellular and metabolic activities such as maintaining stomach lining integrity regulating blood°ow within the kidneys and balancing platelet function. COX-2 is found in the brain, male & female reproductive organs, the kidneys and in bone forming cells called osteoblasts [11] . COX-2 was determined to be an \inducible' isoform expressed in response to a variety of pro-in°ammatory stimuli. In contrast to COX-1, COX-2 expression is usually minimal, but when activated, COX-2 regulates prostaglandin production primarily within the in°ammatory cell. This in°ammatory response is vital part of healing and repairing. NSAIDs exert their pain relieving e®ects thorough COX-1 and COX-2 inhibition [12] . Inhibition of COX-1 \turns o®" some important functions such as the repair and maintenance of stomach lining which results in varying degrees of gastric ulceration, etc. From these observations emerged the need for an anti-in°ammatory that is as e®ective as traditional NSAIDs but without the gastrotoxicity. Such a drug would inhibit COX-2 without e®ecting COX-1. Hence, the development of COX-2 inhibitors. It was anticipated that the newly developed COX-2 inhibitor drugs would block COX-2 but not COX-1 and thus, would have the anti-in°ammatory [11] , [13] properties which would avoid inhibiting prostaglandins and platelet thromboxane and thereby avoiding ulcers and bleeding. Meloxicam and nimesulide, selective COX-2 inhibitors are as e®ective as traditional NSAID S but have similar gastrointestinal side e®ects. Celecoxib and rofecoxib are selective COX-2 inhibitors and are also as e®ective as traditional NSAIDs, but have no antiplatelet activity and lead to fewer gastric and duodenal ulcers than traditional NSAIDs such as ibuprofen or naproxen.
Recent studies [14] on the COX-2 inhibitors approach, has raised many serious questions about the central tenets that support this approach. Firstly, the prostaglandins that mediate in°ammation and pain are produced solely via COX-2, and secondly, the prostaglandins that are important in gastrointestinal and renal function are produced solely via COX-1. Increasing evidence shows that COX-1 (not only COX-2 ) may also be induced at sites of in°ammation and that, conversly COX-2 (not only COX-1 ) also plays a physiological role in several body functions. The cardiovascular protective e®ects of nonselective NSAIDs are lost in the case of COX-2 selective NSAIDs [14] , [15] . These e®ects are mediated through COX-1 inhibitions (in addition, COX-2 has a role in sustaining vascular prostacyclin production). Recent studies strongly suggest that non speci¯c inhibitors may also have speci¯c protective activity in neurodegenaration [14] , [16] . Since COX-2 speci¯c NSAID S and non speci¯c NSAID S have some advantages and some disadvantages associated with them at present a lot of work on both types of NSAID S is going on all over the world and we would like to summarize recent results reported in the literature.
Role of COX-1 & COX-2 in in°ammation
The participation of peripheral cyclooxygenase (COX), interleukin 1¯(1L-1¯) and tumor necrosis factor ®(TNF®) in formalin-induced in°ammatory pain was evaluated using male and female Wistor rats. It was observed that the activation of COX-2 after formalin was unlikely. In the late phase of the formalin test, 1L-1¯& TNF® were involved in in°ammatory pain. In decreasing the in°ammatory pain in the formalin test, non selective COX inhibitors (diclofenac) as well as antisers against 1L-1¯& TNF®, but not COX-2 selective inhibitors, were e®ective [17] . Martinez et al. [18] observed that both COX isoforms contribute to the development and maintenance of local in°ammatory nociception, and thus, it could be expected that inhibition of both COX-1 and COX-2 is required for nonsteroidal anti-in°ammatory drugs (NSAID)-induced antinociceptin in the rat. These¯nding's suggest that therapeutic e®ects of NSAIDs may involve, at least in part, inhibition of COX-1 and COX-2. The role of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) dependent mechanism in the hyperemia of the in°amed gall bladder was studied by Nilsson et al. [19] and it was observed that the iNOS & COX-2 inhibitors played a role in the treatment of mucosal in°ammation with less side e®ects. Igwe et al. [20] observed that not only transcriptional regulation, but also posttranscriptional events are involved in a redox-sensitive regulation of interleukin 1-induced NOS-2 and COX-2 gene expression in the dorsal root ganglia. Overall, interleukin 1¯-induced oxidant stress appears to regulate NOS-2 and COX-2 gene expression primarily at the level of protein translation. Implication of a reactive oxygen species production in interleukin-1¯receptor-activated mol. signaling in the dorsal root ganglia suggest a possible novel target for intervention in the cytokine-mediated in°ammatory process. Expression of various growth factors such as epidermal growth factor (EGF), hepatocyte growth factor (HGF) and basic¯broblast growth factor (bFGF) at the ulcer margin involves healing of the ulcer [21] . The in°uence of EGF, HGF and bFGF applied locally with or without neutralizing anti-EGF, HGF and bFGF antibodies or cyclooxygenase (COX)-1 and COX-2 inhibitors on ulcer healing and the expression of COX-1 & COX-2 during ulcer healing have been studied by Brzozowski et al. [21] . The authors observed that the growth factors accelerate ulcer healing due to enhancement in the microcirculation around the ulcer and these e®ects are speci¯c because they can be abolished by neutralization with antibodies. COX-2 derived prostaglandins and suppression of gastric secretion may play an important role in the acceleration of ulcer healing by various growth factors and the local e®ects of EGF, HGF and bFGF on ulcer healing can be reproduced by their systemic application indicating high e±cacy of growth factors to accelerate this healing. Prostaglandin production [22] via COX-2 appears to mediate the development of acute in°ammatory hyperemia, but nitrergic mechanisms may supervene subsequently. COX-1 but not COX-2 contributes to the maintenance of basal blood°ow in the hyperemic joint at 24h. Wallace et al. [23] studied the e®ects of SC-560 ( a selective COX-1 inhibitor) and celecoxib ( a selective COX-2 inhibitor) or a combination of both inhibitors on gastric damage and prostaglandin synthesis and came to the conclusion that inhibition of both COX-1 & COX-2 is required for NSAID-induced gastric injury in the rats.
Peskar [24] observed that both COX-1 and COX-2 either alone or in concert contribute to gastric mucosal defence. Gastric mucosa speci¯c inhibition of COX-1 does not elicit mucosal lesions despite near-maximal suppression of gastric prostaglandin formation, in normal rat.
When a selective COX-2 inhibitor, which is not ulcerogenic when given alone, is added to the COX-1 inhibitor, severe gastric damage develops. In contrast to normal gastric mucosa which requires simultaneous inhibition of COX-1 & COX-2 for breakdown of mucosal resistance, the acid-challenged rat stomach inhibitions of COX-1 alone results in dosedependent injury which is further increased by additional inhibition of COX-2 enzyme activity or prevention of acid-induced up regulation of COX-2 expression by dexamethasone. It is observed that both COX isoenzymes are essential factors in mucosal defense with speci¯c contributions in various physiological and pathophysiological situations.
The role of the COX isoenzyme in prostaglandin formation and oxidant stress in in-°a mmation was studied by McAdam et al. [25] . Volunteer subjects were administered placebo or bolus injections of lipopolysaccharide (LPS), which caused a dose-dependent increase in temperature, heart rate and plasma cortisol. Dose dependent elevations in urinary excretion of 2,3-dinor-ketoPGF 1® (PGI-M) & 11-dehydro-thromboxane B 2 (T x -M) was caused by LPS. Symptomatic and febrile response to LPS was not altered by inhibition of platelet COX-1 with chronic adminitration of low-dose aspirin before LPS, but the increment in urinary PGI-M & T x -M were both partially depressed. Pretreatment with Ibuprofen, a non speci¯c COX-inhibitor, attenuated the febrile and systemic response to LPS and inhibited prostanoid biosynthesis. Both, a selective COX-2 inhibitor celecoxib and ibuprofen attenuated the pyrexial, but not the chrontropic response to LPS. It is clear from these studies that although COX-2 predominates, both COX isoenzymes are induced and contribute to the prostaglandin response to LPS in human, (ii) COX activation contributes undoubtedly to lipid peroxidn induced by LPS and (iii) COX-2 but not COX-1 contributes the constitutional response to LPS in human. 
Chemical manipulations
Secondary amide derivatives of various-COOH containing NSAIDs, for example indomethacin, were prepared and screened for anti-in°ammatory, COX-2 inhibitory, antiangiogenic and antitumor activity. Many of the tested compounds showed potent activity [26] . A method for converting NSAIDs to COX-2 selective inhibitors have been reported in the literature [27] . Thus, COOH moiety of NSAIDs is converted into an ester ( Figure 1 ) or secondary amide ( Figure 2 ) analogs which are speci¯c for COX-2. For example, the con- version of a free COOH group in indomethacin to Me ester gave a compound which was 132 times more selective as a COX-2 inhibitor than as a COX-1 inhibitor, IC 50 (COX-2) is 0.25 ¹M; IC 50 (COX-1) is ¹ 33 ¹M. By replacing the benzoyl group of indomethacin with 4-bromobenzyl and by extending the acetic acid side chain a series of potent and highly selective COX-2 inhibitors have been synthesized by Black et al. [28] . Out of a number of compounds synthesized, compound 3 has the best in vitro and in vivo pro¯les. It has an IC 50 of 2nM against COX-2, is inactive against COX-1 at 50 ¹M, and is active
in a rat paw edema assay with ED 30 of 0.4mg/kg. Compound 3 show a high level of GI tolerance. Lumiracoxib ( Figure 4 ) (2-[(2-chloro-6-°uorophenyl)amino]-5-methyl benzene acetic acid) is structurally related to dichlofenac, but it is a selective COX-2 inhibitor. Rordrof et al. [29] from Novartis Pharma studied gastroduodenal tolerability of lumiracoxib v's placebo and naproxen in healthy male subjects and came to the conclusion that multiple dosage of lumiracoxib resulted in gastroduodenal tolerability similar to placebo and superior to naproxen. 
Formulation and co-administration
The commulative incidence of both duodenal and gastric ulcers in patients with arthritis receiving long term NSAID therapy can be reduced signi¯cantly by treating the patients [30] with high doses of famotidine ( Figure 5 ). Famotidine competitively inhibits the action of histamine on the H 2 receptors of parietal cells, and consequently reduce gastric acid secretion [31] . Ulcer formation caused by NSAIDs could be prevented by using tetrazole benzothiophene carboxamides in mammals [32] . Conjugates of a combination of selective COX-2 inhibitors and NSAIDs provides a new class of pharmacological active agents which provide the therapeutic bene¯ts of both NSAIDs and selective COX-2 inhibitors, while causing a much lower incidence of side e®ects than are typically observed [33] . Cooper developed a combination of a COX-2 inhibitor and a compound selected from the group consisting of non steroidal antiin°ammatory drugs [34] . A formulation tablet containing ibuprofen 200, celecoxib 100, pregelatinized starch 75, microcryst. cellulose 60, hydrous lactose 50, sodium crosacrmellose 20, collidal silicondioxide 5, sodium lauryl sulphate 3 and stearic acid 5mg have also been disclosed.
A combination of 5-lipoxygenase inhibitor i.e 4-[5-(3-°uoro-4-methoxyphenyl)-3-di-°u oromethyl-1H-pyrazolo-1-yl] bezenesulfonamide and COX-2 inhibitor i.e 6-[(3-°uoro-5-(3,4,5,6-tetrahydro-4-methoxy-2H-pyran-4-yl)phenoxy]methyl]-1-methyl-1H-quinazolin-2-one at 30mg/kg/day orally in mice in the induced arthritis screen reduced incidence of arthritis to (20%) (vs 100% for controls). A formulation containing both is also disclosed [35] .
Development of safer non speci¯c (COX-1 & COX-2 inhibitors) in-°a mmation inhibitors
In addition to various approaches mentioned above for overcoming the side e®ects of NSAIDs, another approach on which a lot of work is going on all over the world, is to develop new non speci¯c in°ammation inhibitors. In search of safer anti-in°ammatory drugs, various types of heterocyclic compounds have been synthesized and screened for antiin°ammatory activity. Here in this review we will mainly focus on the recent work done on the following types of heterocyclic compounds. 4.3.1 Pyrazine and pyridine derivatives. 
naphthylmethyl, thienylmethyl. Fujitake et al. [38] synthesized pyrazine derivatives ( Figure 7 ) and screened them for blood platelet aggregation inhibition and anti-in°ammatory activities. Abe et al. [40] synthesized heterocyclylamino phenol ( Figure 11 ) by the condensation of 2,6-di-ter-butyl-1, 4-benzoquinone with 2-aminopyrazine followed by reduction of the resulting product with Et 2 N-OH. Compound 11 is useful as in°ammation inhibitor. N-(Pyridin-4-yl) nitrogen heterocyclic compounds 12 & 13 which are useful for treating or preventing in°ammatory and immune cell mediated diseases have been synthesized by Kelly et al. [41] . Thienopyridine derivative (Figure 14) is useful as an anti-in°ammatory agent [42] . (Figure 15 ) possesses anti-in°ammatory activity better than ibuprofen in carrageenan induced rat paw edema assay and has been synthesized and reported in the lit. [43] .
The 4,5-substituted imidazolyl [44] and 1,2-substituted imidazolyl [45] compounds have been synthesized for the treatment of in°ammation. Compound 16 in carrageenaninduced rat paw edema and analgesia tests gave 57% inhibition of edema at 30 mg/kg
X, Y and Z are various substituents. orally and 51% inhibition of hyperalgesic foot withdrawal at 10 mg/kg orally. Pyridine derivative ( Figure 17 ) containing compositions useful as asthma inhibitors have been claimed in a Japanese patent [46] . Compound 17showed 72% bronchodialator activity at 30¹g/ml. Braendstroem et al. [47] synthesized an isomeric mixture of 2-(Pyridine-2-ylmethyl sul¯nyl) benzimidazoles (Figures 18 & 19) which inhibited gastric acid secretion in dogs with ED 50 =1.5¹M/kg orally. Saito et al. [48] synthesized aminopyridine derivative ( Figure 20) . The sodium salt of (20) at 100 mg/kg gave 79.8% inhibition of arachidonic acid induced ear edema in For Two tablet formulations containing (26) Pyrimidinedione derivative ( Figure 28 ) is useful as an anti-in°ammatory agent and has been synthesized in nine steps [55] . Lee et al [56] synthesized the pyrimidine derivative ( Figure 29 ) and their pharmaceutically accepted non toxic salts. It is claimed that these compounds possess an excellent inhibitory activity against gastric acid secretion.
Condensation of 1-[(2-iodoethoxy)methyl]methyl] thymine and 2-(dimethylamino) ethyl hexadecanoate in the presence of acetonitrile gave acyclic pyrimidine nucleoside ( Figure 30 ). Compound 30 is useful in the therapy of septic shock, cachexia, rheumatoid arthritis and in°ammatory bowel disease [57] .
A series of 4,6-diphenyl-2-pyrimidine-carboxylic acid amides ( Figure 31 ) showing antiin°ammatory activity greater than acetyl salicyclic acid have been synthesized by Myakushkene et al. [58] . Vainilavichyus et al. [59] synthesized 4-[1-(5-hydroxy-3,5-dimethylpyrazolin-2-yl)]-2-(iso-propylthio)-6-methyl pyrimidine ( Figure 32 ) and reported that the anti-in°ammatory activity of (32) was comparable to ibuprofen. Ranise et al. [60] synthesized acylthio derivatives (Figure 33 ) which showed a platelet anti-aggregating activity invitro superior or comparable to that of acetyl salicyclic acid as well as remark- 
Provided that when all of 
Synthesis of condensed pyrimidine derivatives
A number of condensed pyrimidine derivatives viz bicyclic compound (45) [61] , [66] , (46) [62], [66] , (47) [68] , tricyclic compounds (48) [61] , [64] , [65] , [67] , [68] , (49) [69] , [70] , (50) [69], tetracyclic compound (51) [66] and pentacycic derivative (Figure 52 ) [66] have been synthesized and screened for anti-in°ammatory activity. Many compounds at 100mg/kg p.o. have shown interesting anti-in°ammatory activity which is summarized in Table 1 . [73] . Derivatives of compound 54 were screened for invivo antiin°ammtory, analgesic and ulcerogenic activities and some derivatives of (54) these compounds were compared with those of indomethacin. Their structure-activity relationship was also discussed. Santagati et al. [84] synthesized thieno[2,3-d] pryimidine -2,4-dione ( Figure 64 ) and 5H-pyrimido [5, 4] indole -2,4-dione derivatives ( Figure 65 ) . Some of these compounds showed an appreciable analgesic and anti-in°ammatory activity and low acute toxicity with an optional gastric tolerance.
R3=Me, OMe ,Cl. Figure 66 ) showing anti-in°ammatory activity better than mefeniamic acid but devoid of ulcerogenic activity have been synthesized and reported in the literature [85] . Many pyrimidothiazine derivatives ( Figure 67 ) having invivo activities comparable to acetylsalicylic acid and aminophenazone in an anti-in°ammatory model (carrageenin rat paw edema) and an antipyretic test (yeast induced fever in rats) have been synthesized and reported in the literature [86] .
Bantick et al. [87] synthesized a number of pyrimidine fused compounds (68) which are useful as antiallergic and anti-in°ammatory agents. The above few references have demonstrated the importance of pyrimidines and condensed pyrimidines as in°ammation inhibitors.
Acridine derivatives
Gaidukevich et al. [88] synthesized acridinyl 9-thioacetic acids ( Figure 69 ) and their derivatives ( Figure 70 ) and screened them for anti-in°ammatory, analgesic and antihypoxia activities. A majority of these compounds showed anti-in°ammatory activity equal to that of indomethacin. The analgesic activities of these compounds are 1.2 to 1.4 fold higher than that of analgin. The 9,10-dihydro-9-oxo-2-acridine alkanoic acids (Figures 71  & 72 ) have been synthesized and screened for anti-in°ammatory activity by the rat hind paw carrageenan-induced edema assay [89] . N, N'-Bis(6-chloro-2-methoxy-9-acridinyl)-1,2-ethandiamine bis(tri°uoroacetate) i.e. compound 73 possessing anti-in°ammatory and antiviral activities have been synthesized and reported in the literature [90] .
A number of acridine derivatives (74, 84 and 85 [63] , [93] ) have been synthesized and screened for anti-in°ammaotry activity. Screening results are summarized in Table 2 . The above mentioned few examples demonstrate that acridine derivatives do possess some interesting anti-in°ammatory activity.
Various types of heterocyclic compounds
In this section we will report in brief, di®erent types of compounds possessing antiin°ammatory activity. Synthesis of thiocarbamates (Figure 86 ), mercaptopyridoimidazole ( Figure 87 ) and thiourea derivatives (Figures 88, 89 ) possessing anti-in°ammatory activity have been reported in the literature [62] , [92] .
Compounds 86a,b; 87; 88; 89a and 89b exhibited 27, 14, 17, 22, 18 and 23% anti- thesized by Sohda et al. [99] . Compound 98 in a rat paw edema suppression test showed 94% swelling suppression rate when administered at 3.13 mg/kg once daily over 14 days. 
Development of speci¯c (COX-2 inhibitors) in°ammation inhibitors
In this section we will take into consideration the following points. LPS stimulation induced COX-2 expression whereas monocytes without LPS stimulation exclusively expressed COX-1 on Western Blotting Analysis. LPS-stimulated monocytes (COX-2) and unstimulated monocytes (COX-1) were then used to determine the COX selectivity of various NSAIDs. The respective mean IC 50 values for COX-1 and COX-2 IC 50 (¹M), and the COX-1/COX-2 ratio of some of NSAID presents Table 3 . The percentage inhibition of COX-1 activity at the IC 50 of COX-2 also showed a wide variation among these NSAID. Use of human monocyte in bioassay system to access the inhibitory e®ects of various NSAIDs on COX-1 & COX-2 may become a clinically useful screening method. Models for selective COX-2 inhibitors were established and their mechanisms of anti-in°ammatory e®ects were studied by Hu et al. [101] . Model for COX-1 was set up with cultured bovine arterial endothelial cells by detection of 6-keto-PGF 1® in the supernatant of cultured cells. Three di®erent COX-2 models were established with murine peritoneal macrophages. The activity of tested compounds for COX-2 were evaluated by detection of PGF 2 production from arachidonic acid in the supernatant of the murine macrophages stimulated with PLS or PMA. LPS and PMA induced COX-2 activities signi¯cantly and dose dependently. COX-1 activities were signi¯cantly inhibited by indomethacin and meloxicam with IC 50 of 5.01x10 ¡10 M and 2.8x10 ¡8 M respectively.
The ratio of IC 50 COX-1/IC 50 COX-2 were 0.53 and 3.04 respectively. The results showed that (i) indomethacin was a COX-1 inhibitor and meloxicam was a COX-2 inhibitor and (ii) the above three models for evaluation of COX-1 & COX-2 activities were e®ective, sensitive, simple, fast and accurate & can be used for screening selective COX-2 inhibitors. The di®erential suppressive activity of nonsteroidal anti-in°ammatory drugs (NSAIDs) on canine COX-1 and COX-2 isoenzymes was evaluated by Kay et al. [102] . Meloxicam and tolfenamic acid inhibited COX-2 with meloxicam inhibiting COX-2 activity 12-times more e®ectively than COX-1 activity. Caprofen was more selective for COX-2 (1.75 times) than for COX-1 and ketoprofen was slightly more selective for COX-1. Thus COX-1 and COX-2 were di®erentially sensitive to inhibition invitro by NSAIDs.
Synthesis of COX-2 inhibitors
With the discovery that COX-2 speci¯c inhibitors may have less side e®ects than non speci¯c inhibitors [103] , lot of e®orts are going on all over the world to synthesize COX-2 speci¯c inhibitors. Some of recent work done in this direction is summarized herewithin. Sui et al. [104] HN-56249(3-(2,4-dichloro-thiophenoxy)-4-methyl-sulfonylamino-benzenesulfon-amide) is a novel potent and highly selective COX-2 inhibitor with a marked preference for the human COX-2 enzyme invitro [105] . Antiin°ammatory e®ect of HN-56249 in rodents were only moderate despite excellent bioavailability and the long plasma half life. It is suggested that these di®ering invitro-invivo e®ects observed could be due to signi¯cant in°ammatory prostaglandin synthesis by COX-1 or to the genetic di®erences between human and rodent COX-2 or to both. Pal et al. [106] synthesized furanone derivative ( Figure 100 ) which exhibited 100% inhibition of COX-2 vs. 33% inhibition of COX-1 at 100¹M invitro. The imidazole derivative (Figure 101 ) is useful as a selective inhibitor of COX-2 and particularly as anti-in°ammatories have been synthesized [107] and reported in the literature. Compound 101 and its derivatives are claimed to be useful in the treatment of in°ammation, pain, fever, prostanoid-induced smooth muscle contraction, dysmenorrhea, premature labor, asthma, bronchitis, cancer, Alzheimer's disease or dementia. Compound 101 gave 89% inhibition of COX-2 at 1¹M invitro but only 37.8% inhibition of COX-1 at 10¹M. A series of heteroaryl modi¯ed 1,2-diaryl imidazoles have been synthesized and found to be potent and highly selective (1000-9000 fold) inhibitors [108] and cyclooxygenase COX-2 inhibitor for the treatment of anti-in°ammatory diseases have been synthesized by Graneto et al. [111] . Pyrazole derivative (Figure 107 ) inhibited COX-2 by 92% at a dose of 40mg/kg orally in rats and hence can be used [112] for treating in°ammation and other processes mediated by COX-2.
Compound 108 inhibit the biosynthesis of prostaglandins by intervention of the action of the enzyme cyclooxygenase on arachidonic acid and are therefore useful in the treatment of in°ammation & other in°ammation associated disorders such as arthritis, in mammals [113] . A similar compound 109 exhibited signi¯cant selectivity for inhibition FR 140423 on oral administration and was two-fold more potent than indomethacin. The increase of (PG)E 2 & thromboxane (TX)B 2 but not leukotriene B 4 in in°amed paws was associated with the development of paw oedema. The levels of (PG)E 2 & (TX)B 2 in arthritic rat paws were suppressed by FR140423 & indomethacin in a dose dependent manner. FR 140423 did not induce gastric lesion in arthritic rats. From these results it can be concluded that FR 140423 exhibit a potent anti-in°ammatory e®ect mediated by inhibition of prostanoids produced by COX-2 in in°amed tissues immunized with type II collagen, with a greatly improved safety pro¯le compared to indomethacin.
Pyrimidine derivative (Figure 111 ) having IC 50 of 18nM against COX-2 vs IC 50 of >91,000 nM against COX-1 have been synthesized and reported in the literature [117] . Compound 111 can be used for the treatment of pain, fever and in°ammation of a variety of conditions and diseases. Ishida et al. [118] 118 and its formulation which are useful as anti-in°ammatory agents and for treating Alzheimer's disease or dysmenorrhea or premature labour, are disclosed in an international patent [122] activity were synthesized by Shin et al. [123] . Pyrazolo [1,5-b] pyridazine derivative ( Figure 119 ) which is a potent and selective inhibitor of COX-2 and thus can be used for the treatment of the pain, fever, in°ammation for a variety of conditions and diseases have been synthesized and reported in literature [124] . A formulation containing 121 was also disclosed [126] . Carter et al. [127] synthesized benzopyran carboxylates and quinoline carboxylates and screened them for COX-2 inhibitory activity. Compound 1,2-dihydro-6-ethynyl-2-tri°uoromethyl-3-quinoline carboxylic acid exhibited cyclooxygenase-2 inhibitory activity and IC 50 value was 1.7¹M.
Safety studies of COX-2 inhibitors
New anti-in°ammatory drugs (celecoxib and rofecoxib) for the treatment of in°amma-tive diseases such as rheumatoid arthritis and osteoarthritis have been demonstrated to inhibit selectively isoenzyme-2 in controlled clinical trials [128] . The anti-in°ammatory and analgesic e®ect of selective COX-2 inhibitors are similar to classic NSAIDs with a lower incidence of adverse e®ects. Borges et al. [129] investigated tolerance to COX-2 inhibitors in patients with cutaneous symptoms attributable to classic NSAIDs. In NSAID sensitive patients with urticaria or angioedema some COX-2 inhibitors such as rofecoxib are relatively safe. However the tolerance pro¯le varies with the drug, which may be related to the di®erential selectivity of the drugs for COX-2 and COX-1. A major mechanism for cutaneous adverse reactions to NSAIDs is represented by COX-1 inhibitions. Patients sensitive to classic NSAIDs requiring analgesic and anti-in°ammatory treatment can be managed properly by controlled oral provocation with new NSAIDs i.e. COX-2 inhibitors. Speci¯c COX-2 inhibitors may result in a lower incidence of adverse e®ects, compared with NSAID, when administered at therapeutic dosages to horses, dogs and cats [130] . Mahadevan et al. [131] studied safety of selective COX-2 inhibitors in in°am-matory bowel disease. Preliminary results of the study suggest that cyclooxygenase-2 inhibitors may be safe and bene¯cial in most patients with 1BD. A placebo-controlled trial to con¯rm these preliminary observations is needed.
Development of in°ammation inhibitors having mode of action other than COX-1 & COX-2 inhibition
Several NSAIDs such as sodium salicylate sulindac, ibuprofen and°urbiprofen cause antiin°ammatory and antiproliferative e®ects independent of cyclooxygenase activity [132] and prostaglandin synthesis inhibition. These e®ects are mediated through inhibition of certain transcription factors such as AP-1 and NF-kB. The e®ects of respective NSAIDs are probably mediated predominantly through alterations of the activity of cellular kinases such as IKK¯, Erk, P 38 MAPK or CdkS. These e®ects are not apparently shared by all NSAIDs because indomethacin failed to inhibit NF-kB and AP-1 activation as well as Erk and Cdk activity. Sodium salicylate or aspirin do not a®ect pPARr however indomethacin was able to activate pPARr. The NSAIDs acting in cyclooxygenaseindependent mechanisms may be of speci¯c use in individual patients because additional e®ects may either enhance the e±cacy or reduce the toxicity of the respective compounds. DiGirolama et al. studied e®ect of NSAIDs on lipoxygenase and cyclooxygenase activities on human colon segments from patients with neoplasia [133] . The two NSAIDs studied i.e. lysine clonixinate (LC) and indomethacin had di®erent e®ects on the production of 5-HETE; while treatment with LC led to signi¯cant inhibition, the 5-HETE levels with indomethacin remained unchanged. Expression of both COX isoformes in colon segments was shown during Western Blotting Analysis with COX-2 levels being 20% higher. The invivo experiments with LC drug continueous infusion and i.v. bolus revealed that signi¯cant inhibition of basal synthesis of PGE 2 and 5-HETE was caused by LC (lysine clonixinate). Wu. et al. [134] reported that IL-10 could exert anti-in°ammatory action by inhibiting the production of pro-in°ammatory cytokines and suppressing their biological functions. 1,2-Substituted benzimidazole derivatives which at 10 ¡6 M inhibited 5-lipoxygenase of RBL-1 cells by 65.9 and 87.6% respectively have been synthesized by Sato et al. [135] . Pyrimidine carboxamides ( Figure 122 ) and pyrazine carboxamides ( Figure 123 ) which are inhibitors of transcription factors (i.e NFK¯and AP-1) and cytokines and have utility as anti-in°ammatory agents in general, have been synthesized by Suto et al. [136] .
Yasufuka et al. [137] synthesized imidazopyridine derivative (Figure 124 ) by the condensation of 2-bromo-3-tertbutyl-4-hydroxy-5-iodoacetophenone with 2-aminopyridine. The compound 124 invitro exhibited an IC 50 value of 1.5x10 ¡6 against 5-lipoxygenase.
N-(Pyridyl-methoxy benzyl)-N-hydroxy ureas ( Figure 125 ) and its derivative ( Figure 126 ) synthesized by Komatsu et al. [138] showed invitro IC 50 of 0.2meuM against the formation of leukotrine B 4 . The4-benzyl-2-phenyl pyrimidine derivatives ( Figure 127 ) which are useful in the treatment of phospholipase A 2 (PLA 2 ) mediated disease have been synthesized and disclosed in an international patent [139] . A number of thiazolopyrimidines as modulators of chemokine receptor activity were synthesized by Austin et al. [140] , thus compound ( Figure 129 ), some of these compounds showed inhibition of interleukin-1 and thus useful as anti-in°ammatory agents. Wachter et al. [142] , [143] 
Future Research
Willoghby et al. [144] demonstrated that COX-2 (identi¯ed by use of speci¯c antibodies) is induced during the resolution of an anti-in°ammatory response, inhibition of COX-2 resulting in persistence of the in°ammation due to the prevention of the synthesis of a range of anti-in°ammatory prostanoids. Inducible prostaglandin E2 synthase, inhibition of COX-2 enzyme synthesis might be future targets for anti-in°ammatory drugs. Willoghby et al. proposed that there exist a third isoform of cyclooxygenase enzyme namely COX-3 and this might be a new therapeutic target for new generation of antiin°ammatory drugs.
Conclusion
This review describes recent advances made to develop safer anti-in°ammatory drugs.
Mode of action of speci¯c and non-speci¯c in°ammation inhibitors and role of COX-1 and COX-2 in in°ammation have been described. Di®erent approaches viz. chemical manipulation, formulation and co-administration, development of safer non-speci¯c (COX-1 & COX-2 inhibitors) and speci¯c (COX-2 inhibitors) in°ammation inhibitors reported in literature to improve the safety pro¯le of anti-in°ammatory drugs have been summarized. In the development of non speci¯c in°ammation inhibitors, the main emphasis has been on the recent work reported in the literature in the¯eld of pyrazine and pyridine derivatives, pyrimidine derivatives, condensed pyrimidine derivatives, acridine derivatives and various types of heterocyclic compounds. A number of compounds have shown good antiin°ammatory activity. A variety of heterocyclic compounds possessing speci¯c (COX-2 inhibition) anti-in°ammatory activity have been summarized. Compounds acting as in-°a mmation inhibitors by mode of action other than COX-1 & COX-2 or COX-2 inhibitors have been reported in this review. With the development of COX-2 inhibitors many questions arises i.e. how safe COX-2 inhibitors are and what will be long term implication of using COX-2 inhibitors. In the literature not much research data is available as to what will be e®ect on human health of inhibiting COX-2. Since positive and negative role of COX-2 on human health is not known completely so research in both the areas i.e speci¯c and non-speci¯c in°ammation inhibitors with better safety pro¯le is needed. 
